AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2024
Jan 8, 2024
6965_rns_2024-01-09_025864af-2eba-425b-a612-b9f19888f331.pdf
Director's Dealing
Open in viewerOpens in your device viewer
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
| OMB Number: | 3235-0287 |
|---|---|
| Estimated average burden hours | |
| per response | 0.5 |
Check this box if no longer subject to
Instruction 1(b).
Section 16. Form 4 or
Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| Mayer | 1. Name and Address of Reporting Person Arie |
2. Issuer Name and Ticker or Trading Symbol Oramed Pharmaceuticals Inc. [ORMP] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Last) 16 Moran Street |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/04/2024 |
Director _ Officer (give title below)_ Other (specify below) |
||||||
| (Street) Kfar Saba |
L3 | 4428890 | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
||||||
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1.Title of Security (Instr. 3) |
2. Transaction 2A. Deemed Date Execution Date, if (Month/Day/Year) any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||
| Common Stock | 01/04/2024 | A | 30,000 | A | (1) | 86,809 | D | |||
| Common Stock | 01/04/2024 | A | 9,325 | A | (2) | 96,134 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. Number | 6. Date Exercisable and | 7. Title and | 8. Price of | 9. Number of | 10. | 11. Nature | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Derivative | Conversion | Date | Execution Date, if | Transaction | of | Expiration Date | Amount of | Derivative | Derivative | Ownership | of Indirect | ||||
| Security | or Exercise | (Month/Day/Year) | any | Code | Derivative | (Month/Day/Year) | Underlying | Security | Securities | Form of | Beneficial | ||||
| (Instr. 3) | Price of | (Month/Day/Year) | (Instr. 8) | Securities | Securities | (Instr. 5) | Beneficially | Derivative | Ownership | ||||||
| Derivative | Acquired | (Instr. 3 and 4) | Owned | Security: | (Instr. 4) | ||||||||||
| Security | (A) or | Following | Direct (D) | ||||||||||||
| Disposed of | Reported | or Indirect | |||||||||||||
| (D) | Transaction(s) | (I) | |||||||||||||
| (Instr. 3, 4, | (Instr. 4) | (Instr. 4) | |||||||||||||
| and 5) | |||||||||||||||
| Amount | |||||||||||||||
| or | |||||||||||||||
| Date | Expiration | Number | |||||||||||||
| Code | V | (A) | (D) | Exercisable | Date | Title | of Shares |
Explanation of Responses:
- (1) Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
- (2) Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 2,331 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
/s/ Arie Mayer 01/08/2024
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.